R&D News | pharmaphorum

News

Merck & Co pens $340m pain drug deal with KCL and Wellcome

Merck & Co has announced a deal with King’s College London (KCL) and Wellcome to investigate a new class of painkillers that could provide an alternative to opioids and their dangerous

News

Group of young multiracial woman with red ribbons in hands are struggling against HIV/AIDS. AIDS awareness concept.

Once-a-month HIV treatment sees promising phase III results

Janssen and ViiV have reported positive data for their once-monthly injectable HIV combo regimen in two phase III trials.

News

AbbVie/Roche seek first-line CLL use for Venclexta combo

AbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new US filing could extend its use into the first-line setting.

News

Lilly claims fast FDA review for Emgality in cluster headach...

Eli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality but could get a leg-up with an indication in episodic cluster headache.<

News

Lilly to sell generic Humalog insulin at half price

Eli Lilly has responded to criticism of high prices for insulin products in the US by launching a cut-price version of its Humalog brand.

News

CHMP okays Sanofi’s Zynquista in type 1 diabetes

Sanofi has moved a step closer to getting its new diabetes therapy Zynquista approved in Europe, with a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).

Merck & Co pens $340m pain drug deal with KCL and Wellcome

Once-a-month HIV treatment sees promising phase III results

AbbVie/Roche seek first-line CLL use for Venclexta combo

Lilly claims fast FDA review for Emgality in cluster headach...

Lilly to sell generic Humalog insulin at half price

CHMP okays Sanofi’s Zynquista in type 1 diabetes

Bayer plans filings for cardiac amyloidosis imaging agent

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks